公司近日发布公告称，上海奥浦迈生物科技股份有限公司于近日收到政府补助款项人民币350.00万元， 属于与收益相关的政府补助。公司根据《企业会计准则第16号——政府补助》等有关规定进行会计处 理。上述政府补助未经审计，具体会计处理及对公司2025年度财务状况的影响以审计机构年度审计结果 为准。 最新公告列表 《奥浦迈：关于获得政府补助的公告》 截至2025年11月13日收盘，奥浦迈（688293）报收于58.5元，较前一交易日下跌0.1%，最新总市值为 66.58亿元。该股当日开盘58.86元，最高59.5元，最低57.81元，成交额达6998.52万元，换手率为 1.05%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - The discussion at the Shanghai Securities Exchange International Investors Conference highlighted the potential for world-class pharmaceutical companies to emerge from China, driven by innovation, supportive policies, and collaborative teams [1][3]. Group 1: Industry Opportunities - High Fei, Chairman and General Manager of Hangzhou Aotai Biotechnology Co., believes that world-class enterprises will definitely emerge in China, emphasizing the importance of industry opportunities, international environment, and continuous innovation [3]. - Xiao Zhihua, Chairman of Shanghai Aopumai Biotechnology Co., pointed out that while challenges exist for Chinese companies to become truly global in a time of globalization retreat, he remains confident that world-class enterprises will emerge [3]. Group 2: Importance of Policy and Market - Zhang Lianshan, Global R&D President of Jiangsu Hengrui Medicine Co., stressed the significance of confidence and policy support, stating that biopharmaceutical companies must first establish value in the Chinese market to generate global value [3]. - The discussion concluded that with improved innovation capabilities and ongoing policy enhancements, the Chinese pharmaceutical industry is likely to nurture world-class enterprises in the future [3].

证券日报网讯 11月13日晚间，奥浦迈发布公告称，公司于近日收到政府补助款项人民币350.00万元，属 于与收益相关的政府补助款项。 （文章来源：证券日报） ...

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

Core Viewpoint - The growth path of international giants in the biopharmaceutical industry is clear, achieved through mergers, integration, and innovative research and development, leading to comprehensive coverage of the upstream industry chain from consumables, equipment to services. This model is feasible for Chinese companies, but it requires time to mature [1] Group 1 - The chairman of Aopumai, Xiao Zhihua, emphasized the importance of mergers and acquisitions in the growth strategy of international giants [1] - The biopharmaceutical industry in China has the potential to develop similar companies, but it will take time for them to establish themselves [1]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 奥浦迈(688293.SH)公告称，公司于近日收到政府补助款项人民币350.00万元，属于与收益相关的政府补 助款项。该补助未经审计，具体的会计处理以及最终对公司2025年度财务状况的影响以审计机构年度审 计的结果为准。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得补助的基本情况 上海奥浦迈生物科技股份有限公司（以下简称"公司"）于近日收到政府补 助款项人民币350.00万元，属于与收益相关的政府补助款项。 证券代码：688293 证券简称：奥浦迈 公告编号：2025-100 上海奥浦迈生物科技股份有限公司 关于获得政府补助的公告 公司根据《企业会计准则第16号——政府补助》等有关规定，公司获得的上 述政府补助属于与收益相关的政府补助。上述政府补助未经审计，具体的会计处 理以及最终对公司2025年度财务状况的影响以审计机构年度审计的结果为准，敬 请广大投资者注意投资风险。 特此公告。 上海奥浦迈生物科技股份有限公司董事会 2025 年 11 月 14 日 二、补助的类型及其对公司的影响 ...

Group 1: Conference Insights - The Shanghai Stock Exchange International Investor Conference highlighted the attractiveness of Chinese asset valuations and significant investment value across three main directions [1] - The conference featured discussions on new opportunities in AI, pharmaceuticals, energy, and high-end manufacturing [1] Group 2: Market Developments - The Shanghai Stock Exchange's Vice President Fu Hao emphasized that the Sci-Tech Innovation Board has strong international characteristics and is evolving into an international market, with increasing foreign participation and a focus on communication with international investors [2] - 360's CFO Zhang Hailong stated that the company aims to enhance safety in the AI world and is fully committed to the "ALL IN AGENT" strategy, positioning itself as a leading digital security enterprise [3] Group 3: Medical Device and Pharmaceutical Industry - Aotai Bio's CEO Gao Fei argued that the strength of a world-class medical device company lies in its niche capabilities rather than sheer size, emphasizing the importance of intellectual property, innovation, and product quality [4] - Optum's Chairman Xiao Zhihua stressed the need for Chinese companies to carve out unique paths to internationalization, focusing on quality and innovation to gain market recognition [4] - Heng Rui Pharma's Global R&D President Zhang Lianshan noted that a truly international pharmaceutical company should achieve $1 to $2 billion in overseas sales from innovative drugs within 15 years [5] Group 4: AI and Robotics - Green Harmonic's CEO Zhang Yuwen highlighted that robots are becoming crucial carriers for AI, requiring deep integration with AI to serve human society effectively [6] - Optum's Deputy General Manager Xu Xueliang discussed how AI is reshaping industrial manufacturing logic, with 2025 seen as a pivotal year for this transformation [7] - Guodian NARI's Secretary Hu Shunjing pointed out that the synergy between vision and brain is key to industrial intelligence, with AI driving advancements in machine vision [8]

Core Viewpoint - The discussion at the Shanghai Stock Exchange International Investors Conference highlighted the potential for Chinese companies to become world-class pharmaceutical enterprises, emphasizing the importance of core business focus, mergers and acquisitions, and capital-driven synergy [1][3]. Group 1: Business Strategy - The chairman of Aopumai, Xiao Zhihua, stated that maintaining a strong position in core areas is essential for building competitive barriers in the biopharmaceutical industry [3]. - Aopumai's culture media business is identified as a core raw material in the biopharmaceutical supply chain, with a long product lifecycle post-launch [3]. Group 2: Mergers and Acquisitions - Xiao emphasized that mergers and acquisitions are crucial for Chinese companies aiming for internationalization, citing Aopumai's collaboration with Hengli Bio as an example of effective synergy in product and service chains [3]. - Aopumai has initiated the establishment of a biomanufacturing fund with a scale of 1 billion yuan, contributing 300 million yuan of its own funds to support the formation of an industrial ecosystem [3]. Group 3: Internationalization and Market Competitiveness - The company believes that true core competitiveness can only be demonstrated through competition in overseas markets, with Aopumai experiencing rapid growth in overseas revenue [3]. - Xiao stressed the need for Chinese enterprises to not only tell compelling stories but also gain recognition from capital markets, advocating for a unique path focused on quality and innovation [3].

Group 1 - The independent director of Aopumai, Tao Hua'an, opposed the company's acquisition of 1.45 billion yuan, stating that the company does not currently have a necessity for mergers and acquisitions [1][2] - This marks the fourth time Tao has voted against acquisition-related proposals during board meetings [1] - Aopumai plans to acquire control of Pengli Biotechnology, which specializes in preclinical CRO services, with a final transaction price of approximately 1.45 billion yuan, reflecting a valuation increase of 56.62% [1] Group 2 - Post-acquisition, Aopumai expects to add 555 million yuan in goodwill, which would account for 849.41% of the projected net profit for 2024 [2] - The CRO industry is characterized by intense competition and significant market segmentation, with risks of price wars and regulatory impacts [2] - Aopumai reported revenue of approximately 272 million yuan for the first three quarters of the year, representing a year-on-year growth of 25.79%, and a net profit of about 49.43 million yuan, up 81.48% year-on-year [2]